Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled In Ferrer's FNP122 ADORE Phase III Clinical Trial For Amyotrophic Lateral Sclerosis (ALS) Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Asceneuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Announces Distribution Agreement with United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Verge Genomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Ferrer Internacional

    Menu

    Ferrer Internacional

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ferrer Internacional

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

              Details:

              The collaboration aims to co-develop VRG50635, Verge’s potent, orally bioavailable PIKfyve inhibitor, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS), in Europe, Central and South America, Southeast Asia and Japan.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Verge Genomics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferrer Internacional

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)

              Details:

              Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

              Lead Product(s): ASN90

              Therapeutic Area: Neurology Product Name: ASN90

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Asceneuron

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferrer Internacional

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction

              Details:

              The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

              Lead Product(s): Aspirin,Ramipril,Simvastatin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Polypill

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: CNIC

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferrer Internacional

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ferrer Announces Distribution Agreement with United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease

              Details:

              Under the agreement, Ferrer has been appointed as the exclusive, worldwide distributor to commercialise Tyvaso (treprostinil) for the treatment of PH-ILD, a rare, serious and progressive disease without an approved treatment in Europe and many other parts of the world.

              Lead Product(s): Treprostinil Sodium

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tyvaso

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: United Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferrer Internacional

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Enrolled In Ferrer's FNP122 ADORE Phase III Clinical Trial For Amyotrophic Lateral Sclerosis (ALS) Treatment

              Details:

              FNP122 as an oral formulation of edaravone in ALS patients. Edaravone is an antioxidant and free radical scavenger that has been shown to reduce excess oxidative stress and cell death1, playing an important role in the pathology of ALS.

              Lead Product(s): Edaravone

              Therapeutic Area: Neurology Product Name: FNP122

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferrer Internacional

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS

              Details:

              FNP122 is an oral formulation of edaravone, a compound that prevents oxidative stress on a cellular level. Therefore, reducing oxidative stress can delay the progression of ALS.

              Lead Product(s): Edaravone

              Therapeutic Area: Neurology Product Name: FNP122

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Treeway

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY